Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Article Title: Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway
doi: 10.2147/DMSO.S380053
Figure Lengend Snippet: FST knockdown aggravated lipid accumulation in LO2 cells and this effect was inhibited by rapamycin. ( A and B ) The efficiency of FST knockdown in LO2 cells was demonstrated by RT-qPCR and Western blotting. ( C and D ) Oil Red O staining and analysis results of FFA-treated negative control shRNA (NCsh) cells, FFA-treated FST-knockdown (FSTsh) cells, and FFA- and rapamycin-treated FSTsh (FSTsh+RAPA) cells (400×, scale bar: 50 µm). ( E and F ) The protein levels and analysis results of Akt, Akt-Thr308, Akt-Ser473, p-mTOR, and mTOR in FFA-treated NCsh cells and FFA-treated FSTsh cells. ( G and H ) The protein levels and analysis results of ACC1, FASN, SREBP1, ChREBP, and mTOR in NCsh, FSTsh, FSTsh+RAPA cells. β-actin was used as a loading control.
Article Snippet: The primary antibodies were β-actin (#AC026) and ChREBP (#A7360) from Abclonal Technology; SREBP1 (#ab28481) from Abcam Technology; mTOR (#T55306) and p-mTOR (#T55996) from Abmart Technology; ACC1 (#4190), FASN (#3180), Akt-Thr308 (#13038), Akt-Ser473 (#4060), and Akt (#9272) from Cell Signaling Technology; and FST (#AF669) from R&D Technology.
Techniques: Quantitative RT-PCR, Western Blot, Staining, Negative Control, shRNA